Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
Posted: 24 May 2024 Telix today announces the successful completion of CUPID1, a first-in-human Phase I dose escalation study of TLX592 in patients with advanced prostate cancer. TLX592 (225Ac-PSMA-RADmAb®) is Telix’s investigational “next generation” targeted alpha therapy (TAT)…
Pancreatic cancer research receives $8m philanthropic funding boost
Posted: 24 May 2024 An exceptional $8 million, 10-year philanthropic investment will spearhead new treatments for pancreatic cancer and create a new dedicated research centre at WEHI. The centre, to be established thanks to an investment by Australian…
CARTHERICS GRANTED EUROPEAN PATENT FOR MULTIPLE DEVELOPMENT CANDIDATES
Posted: 24 May 2024 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has been granted its second European Patent from the family…
Stem cell medicine advancements to be showcased at reNEW’s scientific meeting
Posted: 24 May 2024 At a Glance: Emerging treatments for muscle, kidney and heart diseases will be among the stem cell projects showcased at the reNEW Annual Scientific Meeting. MCRI Director Professor Kathryn North AC will open the…
Making an impact at Connecting Women Lunch
Posted: 21 May 2024 On Friday 17 May 2024, BioMelbourne Network hosted 591 amazing industry professionals at Connecting Women Lunch – our premier event of the year – and acknowledged remarkable women in healthtech. This year we changed…
Ubiquitin trailblazer elected Fellow of prestigious Royal Society
Posted: 20 May 2024 WEHI division head and pioneer of ubiquitination Professor David Komander has been elected a Fellow of the esteemed Royal Society, the UK’s national science academy. Prof Komander was recognised for his significant research contributions towards understanding…
Nominations Open For Manufacturing Hall Of Fame
Posted: 20 May 2024 Victoria’s most advanced and innovative manufacturers are being encouraged to nominate for the 2024 Victorian Manufacturing Hall of Fame Awards, supported by the Allan Labor Government. Minister for Jobs and Industry Natalie Hutchins today…
Amplia Therapeutics Successfully Completes $4.27 million Fully Underwritten Entitlement Offer and ACCENT Trial Update
Posted: 15 May 2024 Amplia Therapeutics Limited (ASX: ATX) (Amplia or the Company) is pleased to announce the successful completion of its $4.27 million fully underwritten, non-renounceable entitlement offer which was well supported by existing eligible shareholders and…
Federal Budget 2024-2025 update for our biotechnology industry
Posted: 15 May 2024 With the delivery of last night’s Federal Budget, below is a summary of the key announcements impacting our industry. This is the third Budget delivered by the Albanese Government, and their final before the…
BioBeacon 2024: ARCS Australia Landmark Event to Spotlight Life Sciences Startups Register to attend!
Posted: 14 May 2024 Closes: 22 April 2024 Event: 14 June 2024 ARCS Australia Ltd, the peak organisation dedicated to the advancement of professionals in the MedTech, Biotech and Pharmaceutical sector, is thrilled to announce the inaugural BioBeacon…
Novartis, Monash University and Monash Health partner in bold vision for heart health
Posted: 14 May 2024 Today, Monash University, Monash Health and Novartis announced a unique Australian partnership in the fight against cardiovascular disease – Australia’s most significant health challenge responsible for 1 in 4 deaths and claiming an Australian life every 12 minutes.…
Cellular immunotherapy manufacturer secured – Cell Therapies
Posted: 14 May 2024 AdAlta Limited (ASX:1AD) (AdAlta) and Cell Therapies Pty Ltd (CTPL) are pleased to announce that they have executed a Master Services Agreement (MSA) establishing CTPL as AdAlta’s preferred manufacturing partner of cellular immunotherapies. This…
